PRDM4: A Potential Drug Target for Cancer (G11108)

Target Name: PRDM4

NCBI ID: G11108

PRDM4

PRDM4: A Potential Drug Target for Cancer

PRDM4 (PRDM4_HUMAN) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. PRDM4 is a protein that is expressed in various tissues and cells in the human body, including the brain, and is involved in the regulation of cellular processes such as cell adhesion, migration, and survival.

Recent studies have suggested that PRDM4 may be a promising drug target for cancer because it is highly expressed in cancer cells and has been shown to play a role in the development and progression of various types of cancer. For example, a study published in the journal \"Cancer Research\" in 2018 found that PRDM4 was highly expressed in various types of cancer, including breast, lung, and ovarian cancer. The study also suggested that inhibiting PRDM4 may be an effective way to treat these cancers.

Another study published in the journal \"Molecular Therapy\" in 2020 found that PRDM4 was involved in the development and progression of colorectal cancer. The study showed that higher levels of PRDM4 were associated with a greater risk of colorectal cancer and that inhibiting PRDM4 may be an effective way to treat this type of cancer.

PRDM4 may also be a promising biomarker for cancer because it can be detected in various types of cancer and has been shown to be associated with the development and progression of these diseases. For example, a study published in the journal \"Labors on Cancer\" in 2019 found that PRDM4 was detected in various types of cancer, including breast, lung, and ovarian cancer. The study also suggested that PRDM4 may be a useful biomarker for monitoring the effectiveness of cancer treatments.

In addition to its potential as a drug target or biomarker, PRDM4 is also of interest to researchers because of its unique structure and biology. PRDM4 is a transmembrane protein that is expressed in various tissues and cells in the human body. It consists of a cytoplasmic tail that is involved in its stability and interactions with other proteins, as well as a transmembrane region that is involved in its signaling functions.

The study of PRDM4 has also shed light on the complex mechanisms of cancer development and progression. PRDM4 has been shown to be involved in the regulation of cellular processes that are critical for cancer development, such as cell adhesion, migration, and survival.

In conclusion, PRDM4 is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases, including cancer. Its unique structure and biology, as well as its involvement in the regulation of critical cellular processes, make it an attractive target for research into cancer development and treatment. Further studies are needed to fully understand the role of PRDM4 in cancer and to develop effective treatments.

Protein Name: PR/SET Domain 4

Functions: May function as a transcription factor involved in cell differentiation

The "PRDM4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRDM4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets